Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug;29(4):491-492.
doi: 10.5021/ad.2017.29.4.491. Epub 2017 Jun 21.

A Case of Nail Psoriasis Improved by Treatment with Golimumab in a Psoriatic Arthritis Patient

So Young Jung  1
Affiliations

A Case of Nail Psoriasis Improved by Treatment with Golimumab in a Psoriatic Arthritis Patient

So Young Jung. Ann Dermatol. 2017 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST: The author has nothing to disclose.

Figures

Fig. 1
Fig. 1. (A) Erythematous patch, swelling of distal interphalangeal joints with oil spots and nail plate crumbling on the right second and fourth fingers, and left thumb. (B) Improvement with respect to nail psoriasis after treatment with golimumab for 24 months.
See this image and copyright information in PMC

References

    1. Radtke MA, Beikert FC, Augustin M. Nail psoriasis-a treatment challenge. J Dtsch Dermatol Ges. 2013;11:203–219. - PubMed
    1. Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57:1–27. - PubMed
    1. Garg A, Gladman D. Recognizing psoriatic arthritis in the dermatology clinic. J Am Acad Dermatol. 2010;63:733–748. - PubMed
    1. Byun SY, Kim BR, Choi JW, Youn SW. Severe nail fold psoriasis extending from nail psoriasis resolved with ustekinumab: suggestion of a cytokine overflow theory in the nail unit. Ann Dermatol. 2016;28:94–97. - PMC - PubMed
    1. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60:976–986. - PubMed

LinkOut - more resources